Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Total revenues	$ 35,340	$ 18,032
Americas
Disaggregation of Revenue [Line Items]
Total revenues	3,732	4,929
EMEA
Disaggregation of Revenue [Line Items]
Total revenues	4,127	6,282
APAC
Disaggregation of Revenue [Line Items]
Total revenues	27,481	6,821
Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	30,690	10,226
Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	4,650	7,806
Performance Enzymes
Disaggregation of Revenue [Line Items]
Total revenues	33,099	14,229
Performance Enzymes | Americas
Disaggregation of Revenue [Line Items]
Total revenues	2,553	2,871
Performance Enzymes | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	3,065	4,537
Performance Enzymes | APAC
Disaggregation of Revenue [Line Items]
Total revenues	27,481	6,821
Performance Enzymes | Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	30,690	10,226
Performance Enzymes | Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	2,409	4,003
Novel Biotherapeutics
Disaggregation of Revenue [Line Items]
Total revenues	2,241	3,803
Novel Biotherapeutics | Americas
Disaggregation of Revenue [Line Items]
Total revenues	1,179	2,058
Novel Biotherapeutics | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	1,062	1,745
Novel Biotherapeutics | APAC
Disaggregation of Revenue [Line Items]
Total revenues	0	0
Novel Biotherapeutics | Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	0	0
Novel Biotherapeutics | Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	$ 2,241	$ 3,803